Speakers

Alexandria Petrusich

Head of Translational Medicine

Graphite Bio

Allison Intondi

Senior Director, Head of Clinical Operations

Graphite Bio

Angela Johnson

Senior Director, Regulatory Affairs

Sigilon Therapeutics

Beverley Francis-Gibson

President & Chief Executive Officer

Sickle Cell Disease Association of America

Gabriela Denning

Vice President, Research & Development

Expression Therapeutics

Clark Paramore

Head of Value Demonstration, Vice President HEOR

bluebird bio

Brian O’Mahony

Chief Executive

Irish Haemophilia Society

Ian Winburn

Vice President, Global Medical Lead, Hemophilia, Endocrine & IEM, Rare Diseases

Pfizer

Julian Down

Executive Director, Gene Therapy

Poseida Therapeutics

KaiHsin Chang

Director, Ex Vivo Pharmacology

Editas Medicine

Leisha Kopp

Applications Scientist

Mirus Bio

Lesha Shah

Assistant Professor, Medical Director, Child, Adolescent & Family Services, Icahn School of Medicine at Mount Sinai

Mount Sinai Health System

John Pasi

Professor, Haemostasis & Thrombosis

Barts & the London School of Medicine

Mark Trusheim

Strategic Director, NEWDIGS & Visiting Scientist

MIT Sloan

Nick Li

Senior Director, Global/US Market Access Lead

UniQure

Wendy Pang

Executive Director, Research & Clinical Development

Jasper Therapeutics

Nicolas Garnier

Director, Patient Advocacy

Pfizer

Paul Monahan

Consultant

Previously Spark Therapeutics

Palani Palaniappan

Chief Technology Officer

Aruvant

Richard McFarland

President

Standards Coordinating Body (SCB)

Pablo Rendo

Global Project Head, Red Blood Disorders & Rare Disease Gene Therapy

Sanofi

Rattan Menzies

Head of Treatment Center Operational Readiness

bluebird bio

Steven Arkin

Executive Director, Clinical Research, Rare Diseases Research Unit, Pfizer Worldwide R&D

Pfizer

Alexandra Hicks

Head of Dupixent Research, Immunology & Inflammation Research Therapeutic Area

Sanofi